title: Long-term bone marrow cultures (LTBMC) from essential thrombocythemia (ET) patients with or without JAK2617V>F mutation.
abstract: Approximately half of essential thrombocythemia (ET) patients and almost all with polycythemia vera (PV) bear the activating JAK2617V>F point mutation, which arises at the multipotent haemopoietic progenitor cell level. Although ET is mainly characterized by megacaryocyte proliferation, the cases that are positive for the JAK2617V>F mutation also show increased bone marrow cellularity and higher erythrocyte and granulocyte counts. After establishing short- and long-term bone marrow cultures we found that the frequency of committed haemopoietic progenitors in the bone marrow, was not increased in JAK2617V>F positive ET compared to the negative ones, whereas in long-term cultures (LTBMC) JAK2617V>F positive ET display a growth pattern more similar to that observed in LTBMC produced by PV marrow cells. Our data support the notion that JAK2617V>F positive ET and PV represents a continuum spectrum of alterations within the same disease.
authors.affiliation: Department of Haematology, Democritus University of Thrace, Alexandroupolis, Greece.
authors.forename: E
authors.initials: E
authors.lastname: Spanoudakis
authors.forename: D
authors.initials: D
authors.lastname: Margaritis
authors.forename: I
authors.initials: I
authors.lastname: Kotsianidis
authors.forename: G
authors.initials: G
authors.lastname: Georgiou
authors.forename: G
authors.initials: G
authors.lastname: Tripsianis
authors.forename: A
authors.initials: A
authors.lastname: Anastasiadis
authors.forename: A
authors.initials: A
authors.lastname: Karakolios
authors.forename: D
authors.initials: D
authors.lastname: Pantelidou
authors.forename: P
authors.initials: P
authors.lastname: Panayiotidis
authors.forename: G
authors.initials: G
authors.lastname: Bourikas
authors.forename: C
authors.initials: C
authors.lastname: Tsatalas
mesh_terms: D019943:Amino Acid Substitution; D002478:Cells, Cultured; D006410:Hematopoiesis / Q000235:genetics*; D006412:Hematopoietic Stem Cells / Q000473:pathology; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D017354:Point Mutation; D011087:Polycythemia Vera / Q000473:pathology; D013920:Thrombocythemia, Essential / Q000235:genetics* / Q000473:pathology
chemical_list: C507924:JAK2 protein, human; D053614:Janus Kinase 2